-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 NrIgDVlHwxEQt6wsf8FcDzfMK9AqM8o/VFIB4RwR1aS22mvM7E1USZ7yktLXxItW
 d6aVD4tIwFnKNom+153aAw==

<SEC-DOCUMENT>0001193125-10-008838.txt : 20100120
<SEC-HEADER>0001193125-10-008838.hdr.sgml : 20100120
<ACCEPTANCE-DATETIME>20100120160742
ACCESSION NUMBER:		0001193125-10-008838
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100120
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100120
DATE AS OF CHANGE:		20100120

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		10536396

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K </B>
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman"
SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Date of Report (Date of Earliest Event Reported): January&nbsp;20, 2010 </B></FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as
Specified in Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 200, Broomfield, CO 80021 </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s Telephone Number, Including Area Code)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
January&nbsp;20, 2010, ARCA biopharma, Inc. issued a press release announcing that the paper &#147;An Alpha-2C-Adrenergic Receptor Polymorphism Alters the Norepinephrine-Lowering Effects and Therapeutic Response of the Beta Blocker Bucindolol in
Chronic Heart Failure&#148; was published in the January 2010 edition of the peer-reviewed journal <I>Circulation: Heart Failure</I>. The press release is attached as Exhibit&nbsp;99.1 hereto, the contents of which are incorporated herein by
reference. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman"
SIZE="2">(d) Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA announces publication of bucindolol data in <I>Circulation: Heart Failure</I>&#148;, dated January&nbsp;20,&nbsp;2010.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: January&nbsp;20, 2010 </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman"
SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;M<SMALL>ICHAEL</SMALL> R.
B<SMALL>RISTOW&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Michael R. Bristow</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>President and Chief Executive Officer</B></FONT></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA announces publication of bucindolol data in <I>Circulation: Heart Failure</I>&#148;, dated January&nbsp;20,&nbsp;2010.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">

<IMG SRC="g26641g98f68.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman"
SIZE="2">Derek Cole </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Investor Relations&nbsp;&amp; Corporate Communications </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2163 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>derek.cole@arcabiopharma.com </U>
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA ANNOUNCES PUBLICATION OF BUCINDOLOL DATA IN </B><B><I>CIRCULATION:</I></B><B> </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>HEART FAILURE </I></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Data from the
clinical study BEST indicate that in the study norepinephrine lowering and </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>clinical therapeutic responses to bucindolol
were strongly influenced by alpha-2C- </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>adrenergic receptor genotype </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Data suggest potential use of genetic biomarkers to define which patients are most likely to </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>respond to the pharmacologically unique beta-blocker bucindolol </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO,
January&nbsp;20, 2010</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular disease, today announced that the paper &#147;An
alpha-2C-Adrenergic Receptor Polymorphism Alters the Norepinephrine Lowering Effects and Therapeutic Response of the Beta Blocker Bucindolol in Chronic Heart Failure&#148; was published in the January 2010 edition of the peer-reviewed journal
<I>Circulation: Heart Failure </I>(<U>http://circheartfailure.ahajournals.org</U>). The paper concludes that in the Beta-Blocker Evaluation of Survival Trial (BEST) adrenergic polymorphism substudy, the norepinephrine lowering and clinical
therapeutic responses to bucindolol were strongly influenced by the alpha-2C adrenergic receptor genotype. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;These data indicate that in
heart failure patients in the study, the norepinephrine lowering effects of bucindolol are under genetic&nbsp;control, and that the degree of lowering may be kept in a therapeutic range by baseline screening using alpha-2C-adrenergic receptor
genetic biomarkers,&#148; said Michael R. Bristow, President and Chief Executive Officer of ARCA. &#147;Furthermore, we believe alpha-2C-receptor genetic biomarkers may be combined with the already reported beta1 receptor position 389 genetic
biomarkers to define which patients are most likely to respond to this pharmacologically unique beta-blocking agent.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adrenergic
activation as most commonly measured by systemic venous norepinephrine levels is an important determinant of&nbsp;outcomes in chronic heart failure. Adrenergic activity is generally thought to be regulated in part by cardiac prejunctional
alpha-2C-adrenergic receptors, which exhibit genetic variation in humans. Bucindolol is a novel beta-adrenergic receptor blocking agent that lowers systemic norepinephrine in heart failure patients and thus is also a sympatholytic agent. This BEST
substudy investigated whether alpha-2C-adrenergic receptor polymorphisms affected sympatholytic effects of bucindolol in patients with heart failure. In this
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
study, patients who were homozygous for, or carried only, the wild type (&#147;Ins&#148;) alpha-2C- receptor gene (87% of the total) had mild&nbsp;reductions in norepinephrine, which were
associated with clinical therapeutic responses that were enhanced compared to the&nbsp;entire cohort investigated in the substudy. In contrast, the 13% of patients who carried a deletion (&#147;Del&#148;) polymorphism in the alpha-2C-receptor gene
had much greater degrees of norepinephrine lowering, which compromised clinical efficacy. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px;padding-bottom:3px;"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Gencaro<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:3px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride) is a pharmacologically unique beta-blocker and mild vasodilator being developed for the
treatment of chronic heart failure (HF). Gencaro is an oral tablet formulation, dosed twice daily. Gencaro is considered part of the beta-blocker class because of its property of blocking beta-1 as well as beta-2 receptors in the heart, preventing
these receptors from binding with other molecules that would otherwise activate the receptor. Because of its mild vasodilator effects, the Company believes Gencaro is well-tolerated in patients with advanced HF. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA biopharma </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:3px;"><FONT STYLE="font-family:Times New Roman"
SIZE="2">ARCA biopharma is dedicated to developing genetically targeted therapies for heart failure and other cardiovascular disease. The&nbsp;Company&#146;s lead product candidate, Gencaro</FONT><FONT STYLE="font-family:Times New Roman"
SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild
vasodilator being developed for heart failure. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted heart failure treatment. ARCA
is collaborating with Laboratory Corporation of America to develop the companion genetic test for Gencaro. For more information please visit <U>www.arcabiopharma.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release contains &#147;forward-looking statements&#148;
for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the impact of genetic biomarkers on patient response to Gencaro and the use of such biomarkers to
predict therapeutic response. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a
result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business objectives and operational
requirements; the Company&#146;s ability to complete a strategic transaction to support the continued development Gencaro, and/or obtain additional financing; the Company&#146;s ability to identify, develop and achieve commercial success for
products and technologies; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s
filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2008, the Company&#146;s quarterly report on Form 10-Q for the quarter ended September&nbsp;30, 2009 and subsequent
filings. The Company disclaims any intent or obligation to update these forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g26641g98f68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g26641g98f68.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`3P#A`P$1``(1`0,1`?_$`,8````%!0$`````````
M```````'"`D*`@,$!08!`0$```<!`0$``````````````0(#!@<("00%"A``
M`00!`P,!!0,(!@8*`P```0(#!`4&`!$'(1(($S%!(A0)43(5@9%"4B,S%A=A
M<9*R)`KPH;'!0]31-$0U=296EK8Y-D<9$0`!`P,"!`,#!P8+"0`````!``(#
M$00%(08Q01('46$3<2((@9&AL3(5"?#10M(C%'*2LG.3)#145387P5)#8T2D
M)74X_]H`#`,!``(1`Q$`/P">+G&>8SQU0S<FRZUB4]+`0%/2I+FRG'%`^G%B
ML)!=E3'U#9#:`5'5I;SWSM;8&$EW!NJ[9:XZ%I+B3J?)HYGY0O;8XS(Y6=MK
MBX_5N''4:Z#QX)OG)?J,1A/=CX/QPY9PFU*[)F0W::U^2W^@XFOKXM@[%!^Q
MU8.N;^\/Q+,59Y5]KL;!LR&,:2&S3SNAZM>08R3BLQ8SLW--;>MD[E\,E.#6
M!U/(DN&JU*/J"9XX4E/$=#Z:TA3:OXFL_B!Z;_\`<WZP(U;S?Q(-]20^I'M#
M'%_(?OT^O_;+UP]GL=)+Z;K^8#^;;^NL]WSVSQIEEQ7%%`5/LK=:0,DM`5!+
M[K/4FF]F[>YU7E_$7[@16K;MVS\=Z3HRX?UZ?4AQ:1_9O(J>+L_AWSR0G(S`
M,%:^DW]=:E[ZAN:Q@V7^)Z%'<H[I_B:S[BA!V<4C>F`.Q]FYZZ\L?XD>]R:2
M[1QS26M=_;I^!`)_Z;E5>B+LMBIFM,>1F+G`Z>DWD?X:/7B3SCP+D&SB8]DM
M:]@MW.6VS!>G3&9E%.D+6&Q'%@@,N0)#CA`0A]M._P!NMANSGQW=M^XUW'A-
MQ-&+W#)(&!C7&2/J.FKW!AI7GTJR]S]K<S@NJ:TK<6C14FG2X`<=`2#\A2U$
M2E+]J$@[#]+J=]]R![0-QT^T==;T->UP,K"'6I8'-<->JM?D\/G6+CU=98/T
M>*N>N?<D?GU,"'"K>"`M.K=0AZY_5'YSJ**T]-1'0X_(7'8CLM*?>>>?0TEE
MIH+6\ZZ7"E+;3;:"HK40E*022`-$6HQW*Z++JBOR/%;BGR3'+>/\U4W]!9P[
MBFLHP66_F(-I`>>AS&2XE20II2@"A0.QT1;SUS^J/SG1%XJ1V@J4`$IZJ/N2
MGWJ4>@"4CJ2>@&B+#CW5=+)$:=7R.NP]"PB/%70$'9IU>P4.H]^VB*I^VB1@
M3(E0F`/:7YL5I(`.Q)+CZ=A^31%Y$NJZ<M28<Z!,*1N40YL:6X!OL26XSCJM
MA]O3;1%F>NH="CM._L)!(_*G<==$0]<_JC\YT1#US^J/SG_H.B+47F48_C,%
M=IDMW2XY6-=WJ6-_;0::"@)'<HF98/,1@$H&YW5T]^VB(ED>7/BPY-->CR6\
M?S-[NQ,3^<7'WS/>-P4^FG(5$J!'W?:/?HB-"CY)P7)VDR,9S7"\DC*(2)%#
MEE';,DGW!R#,D(4K;V#?1%UR9"E`*[``=]NI)W2HI5[MMMQTT15>N?U1^<Z(
MO4ODJ">SJ??N`D=#MOO]I&WY=$6AH\OQS)TV2\;OJ+(4TUQ.QVZ-%<0+@4^0
M5;GIVE):J@/O)@6M<LA+T9WM?;4H=R1HBWOKG]4?G.B*I#I4H)V`WW_U`G1%
M?T1,\^?&:6MORG6X(''/P3&*&NL1"#BD(E6]Z)!<FE&_8M<:`$H2HC=.ZMM<
M8?Q"M_Y;,]R8^UXH,+8VUO.\-/O2&=G4013@*::E;#=JL/'#B6YN-P%Q)(]I
MKR#2`/DYI-F"\?2+YP"*T'[!".Y$175Z6P@;@176QV.K2G<E(ZJUI_L?MQ=[
MMFDC<QT9CUB@#=2UNI-.=-.2R+E\[-C8W1W#@;<ZF3]$'D*^)2G,7XJCVN.3
MG68I>G4"FI3C0!+CM3*4IF04I">\KJ9C84I.W5+AW]FMQ-I=EL?=;8N+X,ZK
MZRC+I&4]Y@`K5PY!8XNMUSP2MD&D+S1IY'V+M+3AUZ7%P.'!A]TFXJ%MH"P>
MWU%W4Y*E.[)^ZEAQ*EGW(UD#)=CL?/@]N6%K#URWL<KG@-J0"^9VOR"OL7RX
M-V_UR=[Y`!T^/$T!T\?SHG,QXM3,M9D*EBK7$KTN,-K6`&_E(#?:_839"QZ,
M=MY22YWG91[@D>S6OV_NSL0R\\>+HVUM6B,R`>[4"A;7Q!!!'B%=6)W!<QQ1
M]0(<:T^=)4R2@%9+=#2_60A2DEQ25-(>[%[[M=X"TI5V]/?K4'<&&FP>3>VP
M#;?(-=5DG`N<#ITD:DGVK)]E</RD'3>2-%N1[P)Y%/9>)N:6&=<&XE9VSKDF
MRJS-QN3*6I3CLI-))7'B/NK62M;BH2F^Y1))4#KO]\(G<'(=P>Q6,S63ZI+V
M%[K=YXDF,-J#YCJ%5J/OVPAP>X9[:W`+9#U`#SKP2E0-AM]FMF@6N'4T4:59
M43#'&&'B$-151-/_`%DO)V?XZ^&^6T>'29/\U>=G)/$N!0ZYMV1;,P[2N?F9
MWD<*-%!DK1CV&QY2RH=&W'4D[`Z(D8?Y=3R3;S?Q[SSQEMY@5=<&WPR'#8KC
M@4I7&^<O/3/0B;J*U1Z3*$24'ILE$IO[1HBD8$$>W1%@V5=#N*Z?46,=J776
ML216V$1\=S$N!.:7&F17@""69$=U2%;$'M/0CVZ(HRWU?/IM^-?`'BQDOD5X
MZT&2\,9CA.1XBQ,J\2S_`#B/B>25>1W\>DGLSJ*PNK%NMG,"6AR.]$6QLH=J
MTE)W!$D/Z)'A)P_YJ1.=,Z\DY>?\BPN.+O#<:QS$9?(V:U=&IZ^J[2TL;.U7
M5W<:PL'O\(EMMM3R&D`'=!)!T1/#>1/T5?&RXX_R.R\6?Y@>.'---33[3",G
MP#D[D+\,G7\",J175&15-GD,Y,BLLWFO16[&<CR&2[ZB5$C;1$W3]'7ZJW.5
MSSE1^'?E'E-AR%%RZ1:X[QSFV2O_`#F:XIFE"Q*>_@S(+OTFY.45-HS`>:CR
M)97,8D-)2IQ:'!HBEA'IOO[M]_R#<_F`T11]OJ??6*L/'_-)'B_XDUL3._(:
M3+BX]D>3JA)O:;CR^M_08K<7H:1)+>6<B/NS&=V'`J%"4\@/=[@6T@BVWC#]
M(>?R?&K.;?J<Y]GODAS/D++5U_*_+,SNW>,^/VIB4RF:6=4U<JOA7]LPEP(?
M89#%3'(+33*^TJT1.63/IZ>"EC0G&9/B%X]&E+!8,5KBW%(CR6PE((9L8M>S
M8L.C;HXAT+/V[Z(H\OU1_HM8WP5QUE7D_P"%J;W':+`XTC)>1>&6;BUG"LH8
MKC3TG)^.[%;XLPQ2I!?G5C[KZ?ED+6RX`GTR12AN`LQC\B<&\.9_%=0_'S7B
MW`,G:=;<#K:OQG%*F<[VN>U9#SR@2223HB-O1$ECS5\B:_Q4\9>5.<910_9X
MK0.1,+J"`M_(.0LB6F@P>DCL;^I(7,R.PCE;:`I990YL-@=$4;W_`"]OE+=U
MG//.OC9R-9R)%GS0];\R53EJ'F93G+%%.<1R)&6U*4'&["\J9(EK21ZI56J[
MO?HBET_[O]_7_9HBN-?O$_E_NG1%F:(F8?,&(W(\EK?UV6Y+?\-8F`VO=&W^
M!=WV<;(<WUPH^-Z*.\^*F\M+FLEO]V8ZK!QUB.M=?J6SG;EO3L*.1OV_7F_E
M!=UQ;B-!8"(F)<KH+1#C(C_B+;GR7S#1"FO3MHQ[V7@H?\5L]OO5K*?:'96V
MFPP28.]-CGW"D;9!4%Q_0)]W[1H%:^=RMYUNCF89+8&I`\N:4SD&7PL&MJJ`
M*BOF\B6%0\BX^5E=U(Y6SMT,V5E'BMH0]+L`R2$I4D';N/MUMINS=N-[<9"V
MQ$N/CGWU<6O[3TS6)[2'`%X%>(K6KE9%I8WF9BGG<YS+&,GTZ^(Y`GS_`#(Q
M<<<R&97L3Y,&G<;A0G8L9,:$F+(@Q'V^UUJN=2XHL[A6XW!ZZR/M3*[AS&(^
M],I#;NLX(R'`-H61O!Z@SWCJ`XC@5X;^*"U+3&3UFA.O$BGYEP>;8C`D8\RS
M4S*C'L3=#;]A)G2'W;2ULV2>YB4RRTJ5*3$6GHUNEM:CN=69O;:%DS;HEVX^
M&RVO,'O>9*&69Y)+G<6TZ22T>[S7NL,M=&=O42Y_*G`#ZJGGS3>'*-#2QR^F
MN1,F]O?VSIJ&X"%)4%]_R\!I3JPAH^PN*ZC[-<ON\VV]NV;I)\:3-.P$]?@?
M'\BLU;?R-Q*UD;^#B`E^^#*/3X)C(VV"<LR<#^KUV-=(/P^/_G:'_P!S=?R8
M%A;NK_FYG\V/K*6)K=J/[/Y>*L)W%>'<#X1W'N`VZCV[@>X]=]M3J"9)X_%?
MYT?5(Y@SJS81?<!^"&#6W`>(,.A$BCO^<.384B%R=:I;6%LR)=%CZY%<%)W"
M-D*!!(.B)@/QAO+'Z8'U=9?'>23'ZW`H?)5SPMD,F4XXEB5Q5R5(B2\"R)U>
M_IN(A+GU<Q)5W%'IN#<;*T13LDG=*?N]-P.W?M[0H]O:2$[@IVZ^PZ(O=$31
M?USO_K6YI_\`'N,O_GU#HB0+_EI1V\7^6A)__97&P``W)*L5O=AMT/OT12..
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MVM)Z*2HZ(M-@V$8IQKA^-\?X)15^+X9A]1"H,8QRI:4Q64=+7,HCP:R`RMQU
M;<2*T@)0DJ40/?HBZE1*02/:.HZ[`']8G8[)3[3_`$:(F5/*^>/+SZD/C!X:
MUZ_Q'C#QJ9;\O/(MI/[:!)R*M"(W$&(VJ04H]55E,;EEL_$6I._;\.X(F$?J
M&XS??3H^K+%YPP:(_`H;3,Z+R0Q!IA*VHEE49+9/M<IXR$H/8J,;)%O'+.^W
MR\U/3[NB*;GA>6T>?8CB^=8O,;L,:S3'J7+*"P84"S-ILAKHUE6OCH/C5#?1
MN/T?8>NB+JVOWB?R_P!TZ(LS1$SIY83$QO)BW]2,R^G^'L1W^8;<+?:8#I4`
MIIYI7M_-KAS\9EW;Q?%?>13VXF'W9CN9'_"=S:6GZ5LWV[B<_8,9;)TGUYM-
M/]X>2.;B*;)LF6%PL)QB:PVAM;]C-BS(M6RA93\4FPEV7R2W2-]T@*4HC;8Z
MV,[,WLGIP/L,)CR6MZ@^XD>U@(`U+S.VA\-?D5C[F9>0B0&Y<WK!:``TDU\N
MDGYEQW-TN5AO+S.2/ICN8[E=34LU5C7O=]+%L::&W5V50B0DD-O0W$!QI!'Q
MMKW`.VK1[]397MOWB&Z;IPEV?F;>-C+J(NEM[:75KH^HE]&FHJZNG4:.'+V[
M7`RFWY,6P`W5N2X]6A/.IX<:(V*3F6*Q5-L"8P$/)2VE2'=^T=H`5OO\?:/R
MG66]N][+48.+"P75M(V)IZ'-<'&1[JT#@PUH"[2H&@U7R;_;#X!ZEV*#CQ1G
M5[DV7A3+KE'CEI;6,B5:HI\@DMMSV(,P_P"$<ALJ6TM1DMM]Z4[A?Q#VZRY:
M2YA^PVW&0@QUU?OZG.BD>^-U"26"-IE8".DZ]-=>.JMD-A%XV..9T;1I5H!!
M/GH:'Z$A+E^V0VN9'D8U1U<M"2A;2(DZ/):.RNX.)>FK=V!]NP.N<O??+Q!L
MME<8:&RED:6]37/.IYC]HX?/59?VS"T.B<+I[_>&E&T/E4-'UI9_A`[ZW!T=
M6R$_^;,F^%L*"!^W9^[WDJVZ>_6^?X?S6L^'J$-%!]\W7U0K%7=7_-K#_P`L
M?64K[6ZL?V?R\583N*1OY_>3L+Q#\2^7^;"^RG(JC'W<?P&$Y\2[3D/)TJJ,
M4ALM;$R%QY\CYMQL=5,1EZG4$UK]/*'Y\>)GC5CF$T_T\UY_<YK:VG+&:\BV
M?E!Q;BEQG&2Y^^+;\4L*&;"E6-4]'K'8[!C27"XR6CWCN)T1--?6VX\\C,NS
MC`_*/E_Q15XX,W%3!XKL;.OY=Q'E1C),DJU65QBL^2<48BJH+.'5>K&0IX$/
MI8`0H%/4BD^?3&\ED^5/A7PUR1/F(DYA4T:>/>0T=X4ZSFN#-MTUD^^">Y*K
MB$PQ8#?VIE;Z(E]Z(FB_KG?_`%K<T_\`CW&7_P`^H=$3*WT.N">9>8N-O)6S
MXC\L^3_&F;09EAD)^'@N)X+EE%DLZ9C%R[`L<A@9?56$EQZM4TIM*(ST<*0O
MKNK8@B25Y<<F^5_$'EQ2<+_4KS;/O);B#!<OJ,CO\!-_98IQ]RKQM,E*$3+\
M>K,8311Y+R(J%NIC/(6IB?%7%6H!7J:(IM'CS&X,:X7XZE^.%3A]+PM<X[7W
M^`Q,'@PJR@54VC`D-R&HT%*4B>I2E)E%WND!]*TNGO"M$2%/K74%K?\`TV/(
M45(6IRD9PC)9R$%>ZJFDSG'Y5DHA'4MLQMUJ/L2$]QV`T1,_?Y:/(ZMC.O++
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M.`_0(\E_YQ^';O#U[8*D9EXUY`O#DMR'$JEO\=Y`9-U@DQ16M3KK<+:97!74
M)3#0/>-$3ZC7[Q/Y?[IT19FB)E3S1FNUWD?;OA*3OC&)K2EP$!2/E7FBM&X(
M4$K!W_JUPL^.Q\]K\25]>QM+6-Q=A63D*1.^4_("MG^V45O-LN&-_5UF>;A_
M"'FK7'.9FT,8V]Q)C5L%:"ZXMU2RTA?14>JB[AD271T`V2WO[3JGV?WT<I!%
M8YJXD&#J/4'46E[!]KTRT@]5.%2T5YJKN+%1159`T/G/!Q^P/;SKX:)8=3F6
M+Y907,+(Z.M?P*DKF(<3&;!EJ8+.VFO*9JG9+JD!Q=@\M*G5K0M/IC?;H-];
MO[:WGM7>>W[VPSN.@?LW'VCXX;:4->)'%KJ2$N+CZE2-0:B@H5B:ZQ^2QTXE
MM'EES(3UN;4>[S`TX4H*<U108YPMBUAAEG&PVKA/7M>N3\[*F3;1JEL/G'X,
M*1$CV<R0PEE$AO?XDGM3ML#MJ.WML]E=FY'$Y*SPL3;C+V\A`#WR1Q.9Z@#J
M2/(!K'70'BI)KO<F3#[6XD!;&!PTJ``:5Z>-/9KSHN.SW/HUXV]27[T>%D-,
MX_!A7B6FVD3`AQR/^&VC7:$M)<*/V,ELIV40%!(ZZM#?W=#%WT4N`R<C8,K9
M%[;65GN?LB:T=T4J11H!<#2AU7T,+@'5,X:'M<:T/(C\M0D+\AYM83`[`ES'
M'D,#M;;D#YD,^B%([8ZGTK=:[=MDE#A`_JUSBW]OS)Y/)OQM_.;F%KB.N0\!
MXM(J:^VBS3@<0.AO0Q@ETIXU\DYGX+I6G@2`ZY_Q\IR9:3[E`2FFR03[>UQ!
M!_I&NM?P#N-O\/-NZ8%K'9.XD!/,/$5![?=]GFL!=TX2[=_2US3T1BOSG1+$
M*P@!1.P[B`0`=BD=QZ$CV#KUZ:W68"&BNA6/":FH4>;SBR*/YR?4X\7?`FEE
M)LN,.`;`<_>0S41T.QY%S2LL6M7C-D4*6RLQJSY>*L+![7;A2>BD])E!2&D=
M@2WV)2EL)3Z:$)2E"6A^Z2A*0$A"6]@-NFPT1(:^I%XY-^4GAGS5Q;'BMR\G
M1CCV:X'W)V<;SG"5+R*C]%U*'%MN60B+@JV3N6Y"A[]$4=+_`"['DX,)YCY-
M\7,HG*@5G+5.WG6"0;%TLAOD/#F51,BJ(2'E)[)EYC*B\IH`J<<KR!U!T13$
MD[=NX(^$'W*&_;L#L2`#L>FB)HGZYSB/_P":_,H4H(+N0<8H3WD)V4K/J,_$
M2=ALE!)Z^P:(D#?Y:)2?Y8>61"AO_,GC@C922K_\5O0#LA2RGH=^H`V_KT1+
M]^L%X#1O-#QZ?R+":IA7/O#$6QR?CR0RVV)>5TX;^9R;CN0L@+6W=,L^O7@E
M7I6++>VP<7N1,K?0H^H4YPWGK7ACS/;2(''?(.0/CB2TNE.L-\?\F29+[5A@
MUHN6HJK:S-I3*BRRLA,.V;*-DA\[$4N/DKC[&.7>/,ZXNS"&FPQ7/<5O<2R*
M&M/WZN]KI5=)(0L`^HVETK1U!2XA).B*##Q)9<G?1A^I!!:Y0JK21AU;*M,7
MR&S8BO\`RW)?`^43PU'S?&U-@1K*74)BQIYCH_:-3XKT=?83U(IUV$YQA_)&
M)8[GF!Y'595AN75,.]QK)*:4B;57%3/:2]%F1)37<E:5)5VK2=EM.`H6$J!`
M(NJ((.Q!&WV@C_;[1HB+OE+E/`N&>/LLY1Y,R&%BV"X342+O(;N>\VVS'BQD
M!Q,=I!7ZDB?,6I+;#"!ZKKRTH2-SHB1S]-GR8Y)\O."<J\A<]BQ*C&L[YDY%
M3POCC%<Q#ET'#^.3H^/XS&N)C:BJWN)LNOE2)$E>W[1PH'PH&B)"OUK>3KWD
MI7CW]./BZT4UR%Y9\CXT,Y,-Y2W:3BNINV`%V'8H%F+:VS3DG98_:L5+AZI.
MQ(GP>/,%QOC#!</XZQ",U"Q?!\7H,3H(;24(3'J<>JXU1!3VH2E/>IF&%*/Z
M:R5'<G?1%I^8.+L<YJXJY)XBRZ*U+QGDO"\BPVV9>'J!MB]KI,%,MO<;A^&\
M^EYM7M;<:21_010E?I/\N77@O]2.1P[R1(%+3YCD.2>-O(WS7?%KXV0PKMT8
M->S''%!ELHRJ`TUZI`]-BR5^B=$4[2.K]HE)W*@IQ)/57Q(W"BHC<-E1Z@';
M^CV:(MAHB03YF>/%SR;'@YYA$83LMQN"N%.I/4;:7>TW[60V(:E`%5E7NJ6I
M*#T>0>P?$!KG[\;/PW9CNQCX-U[$:'[ILZ>O$*UGB:/<!I6O2-`"#Q64NW.\
M68"Y_=,B?_&O)I7@":5\A5-+M6%KCLS\/MF+"JDQ9#B'85BR_!F1W`/C95&E
ML1WAV].H21KCK-!G=MY.XL+DR0WC'=+X0'`1.%?='#C[!P6?YVPWL?JVY:;6
M2CAJ/D1L5O+CS%;$K4RDAEEY<V4M3H1WRBTN,%*3^EV1E;)'N[CMU.LJ6/>+
M,XZP@QC_`%&VC:>I2NH\]%\A^W8;C4@+H[CF),JMI6?G(P;@5TB.#ZH"D#\0
MFOH((.X4%+)U=-_WSR,UCBKQIDZ;2*;IX\#)+3EYKSVVV(!=S`@5Z/\`8$7F
M6<E/7KAD/3$JEN1VVI!2L+47FV4,J?)W^_(;"2=_:K<^W6*MU=P,UN*Y-Q$[
MH;(P$N(/5J`=-%]?'X%\(B$('I$$N]M58X[XPS_F*_B5&*5EA.;4IA$NZ?C/
MIIJ2,M02Z_+GO!N+^R;/<AM*G'7-NB=?4[7=E]]]XLFRPP=C+<6CY`V6X(<!
M$TG5]:'A[0O3F]TXG:C!+.0)F"H%1J1RHGX>,\#J^,L'QS!ZIPNQ*&O;C&0M
M(0N7+4I3TZ:XD#8.2Y3BEG^@C7Z!.V^Q<7VUV'8[/M0!86<8ZR!2LAXGZ%J!
ME<G-F\M/F):TE?H/!$!Y.8?YDYPBGJ?%GF?ASA>I?JK*-E>19YQK><@9FW92
M7VD0)&*"/>UN.P6F(*G"?FF'G/7[5#X01K)KN*^:YGIDL\$S[P;]&WS*\;N;
MK+R-XK\YL)MN8,A1D",RM^0^(KK(86;MY/(;FWS63MN96Y)E-SK!AIX.-*:6
MRXVDME(`3J"@G]>)(7*U=Q[CT/FV\PC).3VFI8RB[XZI+?'<0GR%3'S$=JJ>
M]GV=E$[8'I)="WE!3H44[`@:(B`\G,)\W<TG,5OC%S7PGP[BDC&W8-[9Y[QE
MD6=YNSD+\B2E5ECLF'D%=0PX2*UQOTTOQW74OI*_9L-$3!F/_P"7,YCQS(:W
M.\?\UZ>@SREND9+49/2<<7D>QK+],M=A^+1+!K+6)#4M4QQQ16$A)"U)[=B1
MHB?6\;.///3`V;JE\C.?^#N:ZIC%)47#;^@XJR##<V3E["TM5=GF#D6[<H[>
MJ^53_B4,1F)+SG5*_:=$2"/*?Z=OU%/-7&(V!\Z>:?"E#QQ'MHM\Y@W%?!^1
MU5;.N*]1762;F=:99)N;@5;FSC+;KR6DNCO[-P-$16^+GT@_-CPDO[_)O&WS
M@XXJT96Q`CY?C69<+6MUBF1HJEO&N>G57\4K?CSX")+B&9##C3K;:RG<IZ:(
MGY^)(O*L'C['8G-E[A&2<GQF'T93=\<TUKC^&SY1E/+BO4]-=V%K:04I@%D.
M)=?5NZ%%.R2-$3!OFI]!=OR&\DLDYJX7Y@Q?A7'\Y+&0Y3B,W$[6W7'Y`5+]
M6UR'&7:NRK6*Z/=N(3,=:[@IN>%+;[0H[$2\O'7QV^I+PC885B^:^9/$W/7$
MU#,@1+QCD#AN[B\GJQ9D(1(KZG-ZC)&4RK-#*`EA^Q1((V'>5>W1$JGRF\/>
M`?,;`S@/.^#QLDA17796.9#!<-3FF&6CB03:8KD$-'SU:ZYVI#K1+D=_M`=:
M<``T1-3\3_36\]_!>WL6/!OR^P?,>))T]ZS/!?DKBUR:5MR6\I]T0;;%7Y8J
MYCY3V.2H+$#UNJUM%9)T1*S1G/UA)<<5S?`/@O2SRCT1DDOFGE6XJ$N;$?-M
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MA3C&M2PIYV?'D.JC-J0%E9!!$YMHBPW3^T_I`!'V^S4[!)7EZ:CR\ES5MBV-
M7RT.7F.4ERXV-D.6E5!LW$>SHTY-8=<2G5MY79^VLN2_*VEO<Q$U+96M+:\C
MPXCEJJ\-Q<0.ZH'ECO&I'T@A:?\`EKQW_P"@L0_]K4?_`"6OA_Z:=NO\%Q7]
M&Q>G[SR?]X/\=WZR'\M>._\`T%B'_M:C_P"2T_TT[=?X+B_Z-B?>>3_O!_CN
M_67J>-N/$K2H8+B2"GJ"G&J-'7W?]@.^C>VFPVR-EML+CNMO-K&"GT%3#+91
MK2P3/<#X/=^LNMAPX5?';AP(L2#&9(]&-$8;BL)'O[68Z4-`CW?"!]FKRL[:
MTQT7[K:0LABX4:`!]`"^?*;N9WJRN-/,DZ?*LO7K4BI4HH2I80MPH2I8;;`+
MCA2"H(;"B$EQ>VPW(&YT1$=Q?S?7\KY9F]%18S?UU;@JVZ^VNKQ,6$5W[LIQ
MI=.Q6,JD.MJ8:CN.+6I[W#X?B!T1'G_7U^WKM_K]VB(KZ/E?&KWDO*>*(46_
M;R##ZR):3Y,NI?CTCK$OT"$P;-?PR71\RG??HKKVGH=$1H:(AOHB]`WW/V;;
M^WWG8>P'IO[]$7@Z]?MT1%#S/S%3<)XK_%=Y17]W%=?^08;I6&5-"<\G_#1I
MLM]YM$$S2.QM?:O<@C;?;1$8]!/E6M%36DZ"JKF657`GR:U;WS"Z]V7&;D*A
MN/AMH.N1O4[%'M'Q`Z(MOHB&B(:(AHB&B(:(AHB&B(:(AHBN-?O$_E_NG1%F
M:(L1[]X3_0-0?5[.BI`\D5K_`$_T_-J+/<;T#AYJ!:'"AX(:C7V?,%)Z,?@A
MI7V?,$]&/P0U0E@9,0Y]:CPT51E(P0S2J&IV,#!0$T\T)<>90U.B+/F7D")Q
M=QCEV</K:+U34OHK([JDH$F[F)^4JH^ZNX$+F/(4>A^!*CHB0SQ5R1E/!W&.
M!SXO'R\@I\^S6M_C3.[*S$6==9/F$X-N.8_3L-O2Y\.KC^FT93A2R\ZA?I`I
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MQFIMV(:TMP(MF[5.2+)=-(6VGL26O\1Z@('8>[1$>/`_,TSEJ-F$"]HHN.95
M@642,6R&'7SEV%2_(:+P:G5<MYJ.XXP^XPM'84]R2G<G8[:(B&\ILE@W_*O"
M?$LCYF=`CVXY`R:FK&3*L;M,#U$8]00HFQ3)F3Y<=:DI4I*$I^-:@A).B(V\
M+YKS:QYKD<09Q@51C+K^)'+JF937Z[LQX8<2D1+50B1HJ9)'<G=K='<D[$CK
MHB/+*\PH<+K197LM;7KRV:^NKHK"YEM<6<DD1*NHKV=Y%A83"DA"$#H`5*(2
M"=$1$N<UY]*YAP_BJ+@-54KM:UW*\GF65ZJUFT>(-EUEM4F/5--Q*Z\F2FPA
MMM;SZ!W@]=$77<W\NS>)\2M;ZMQE=[.KZQRV6F?(<JZ2'#;DL04B?:>BX';*
M;.D!J)#8"GI!^+="`I0(N&P_FSE7.GN.;3'N(FG\'R5,*-E>3NWR&C43'8BG
MK";31%]B["BKI&S"7U?]8>[DHZ)[M$79<Y<RO\18I;W,#'_QZSKJYJQ].:^N
MKIF6)$QFOAH?L.QU3]A/F.EN/#:'KK*2I00V"K1$2&1>7&14.-<6Y@YQ[7MX
M]G4Z!737IEU(1:2WRF,;B5B-*Q%=EV5/7EXAJ2X09*^T(04K2LE5C8UXUK5&
M/CO.N8W/.4'BN9Q_%K*>PQ21EBK`W#TG(Z*MZ_AC^3UC<40JE^U4$[1"ZIYD
M.H[B3N!!1=&T,Z@=4H+(LCIL4J95[D%@Q654)*"](>[EJ6ZZXEF/%C,-]S\J
M9+>6$---I4XXL@)!/34512<LSYVS^KRSC3#,>XXAQ;;DVW<35IR>X4NSK\9K
M?2>N;NXH*U"%UJVXCW<VVJ2M2%)(<`((!$JC?<DI"B@@%*RGX20I:5;*WZ_=
M!'0=#[]$5UK]XG\O]TZ(LS1%B/??_(-$5K1$-$0T1#1$-$0T1(D\N'&K/).$
M\4R>);_ROF94_>9S.JZJQMFWE5#:?PFGFL5D:7(+4QQ:@0$$[>S8[:(C#AXQ
M9\NYEB657E$]C7%_'#B;'!,4M(GR5GDF3-,?*0LIM:CN/X)34T7<5\5[]NLD
MN+2@`#1%K/+3)<EJN/X>)XK$NW+'DNYC8C*LZ:KFVSE%2/E3M_*].&TZX),B
M"LMLA6P(6K<Z(CIXLIOX:P;'\?;HTXU$J83,&KIE.H?FL5#92W"D6ZFU%IJY
ME[J?E)05(0XLI"CMN2)%_&\_(^*L2YCJ$8[<W?.^<<EY4S6U$:LF&1,8F_L*
M')9EJMGY"'C$)B0Y)#Y>[`1V_>W&B)4?!?&C7"O%-9CMO8(F6<9-GDN87`4/
M1>N)P^=MGF%*V'R;*&NUM1^+L;!]YT1):X-Y*K7+GFKFJ=57EUF.=W[E9QQC
MT"HL94[(,;J"[$I8=,\W&5`$=V8RE$AY3B6V2R2LIV&Y$I+QRXHL^,,0LG\H
M=9?SG.\AF9EF*V%^K&AV-DM:F*J*Z/W[=:VZ4J4>BG%+(Z;:(B#Q2VBX_P`@
M\E^1O)&+Y@57&;-\9\?08.,V5G:5&.PDJAOWAJTM"4W"E%@]KR6]U#<(![NI
M$>W&N#S[#D7.><,E@OUEEEL:%CV'4\IGTYM-@]4EGY:38QW?CA7%])"Y#K*O
MB:;4$G91(T1%+,S>_E^3>=(G8+EF2R,#QF#5<7Q&:QQ&-,2;)EN=DV46EPX4
M08KT@`,M+3ZCX9;4VVGN7L2+6^)",RO;?.>3,NH;-S)\YN9K>0Y!>095,S75
M50KY?'<8Q2--0B3.8=?[W'E=H8C,-M@*4YN`1=EY,X[>\I9)Q=PO7PK5&,9%
M>/Y5GE[%C2160\<Q]!":]^<AOY=$F<X7/2;*POO[3L-M]$2M:R!`J:Z#5549
MN%75<2/7P(C*`VW%B1&DL1V$(2=DI;90`/>1[=$20^8\7N.=.8\1XFF5]DUQ
M9A3;&>Y]9O0Y4:KR*R=6IJAQN'-4@1IJFF2KUNQ1+:7UG;<)T1:2IQV3R%R[
MEO+^5XO:Q./N"8<K'.+,2E5<B(+6?0PW)$^_BU;K:%+0AV/VPMD]JBIL=?3W
M!56.`;T\*E9OB<SDMZ_EG*F3XW,B7O)5I,M,BN+R)*J7ZV'$G*9Q;$,>A2FT
M2I5?`A)4]*D+2TSZCC:&PH@D04TCF%M&E7^1LKM7?)7$:&TPS*<GQS%,1.1X
M=5TU<Y)KK;D*W>5&C65S/>":R!&HH1<0W(>66X[RN\CN[=15!<3P!(SO->=N
M0^2,QQJ<[D$2U<P>$_,@S*W&<-PZO+[DTTDV8RTY;6UC*]..TEI)[TAQYU20
M4@D3@VB*XU^\3^7^Z=$69HBQG4[KWW2.@]J@#^;1%;[#^LC^T-$0[#^LC^T-
M$0[#^LC^T-$0[#^LC^T-$0[#^LC^T-$0[#^LC^T-$500OH0H;;C]/=/3;V`$
M)Z[>\$Z(J/34"K=:3N=U!2]R"1TZJ43MM[`?R:(J2UNL'U$@D)&P6GNZ*)1V
MG[P!5O[.I^W1%<"2._<M$`?&"H$;GWN$DJ/YQHBH+!*=E.$([#N`ZH;HW2I7
MQJ4I26]@!T(&WMWT1$%Y&'D6;QKE..\=T,9^7>4DJ+89-99+08_4X]4NH5^*
MOON64YIXN?()6GO[0TV%]Q7LDC1%U/!\"K@<2X%74K<9FJK<;C5["H5Y2WT&
M6IAI+5A/C6^/3K"IG-2+%+J^]#JOC*NX!6^B(UO35M]]&^PZ]P_V;^PC1$/2
M=Z$N'<=>BR$DG<)Z$D]HZ;#<C<;Z(O`V4C;O22-]RM222H'XBKV`DJ]NB*HM
MN="5=>[X.Y9*.J@4CMW`4I/L!]NB+PMN$@]XW[=@"KIT.^X[2@@[#;H>NB*E
M+8[%=BFO3W3OLH%'P]P4%[*"3W.$GW==$57IJ&X4M*CO[5*'=[![3TW.^Y_+
MHB]*%=I]139;&^^Y"4G=8*>_8A)*3T]V^B*I2%G<%6Q('L7LK;N"E?%]X`[$
M;#H`=$5`;4GKW@^S;=>X[]OA40HD$CW`;#1%X4$_=4TE'I[;`IZ))/>H'<I[
M2?8""$Z(@4$=O>MLD[A/<I._P^TM[GX5']+;H?L&B+WL/ZR/[0T15MIV6#ND
- -^WV*!/L/NT196B+_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
